New cancer research centre plans at Oxford Science Park submitted
Architectural practice Foster + Partners has submitted plans for a new cancer research facility and oncology clinic at Oxford Science Park.
The Lawrence J. Ellison Institute for Transformative Medicine announced last summer plans to add to its proposed Oxford scientific campus, which will be a permanent home to research laboratories, a patient clinic, educational facilities, and collaborative spaces in support of the Ellison Institute’s research and healthcare strategy.
The Ellison Institute acquired the 3.5 acre Plot 18 from Magdalen College, part of Oxford University, through a 150-year land lease arrangement. It is an interdisciplinary, patient-centred research centre that provides cutting-edge cancer care and wellness services, undertaking research initiatives that span the scientific spectrum to change how cancer and other diseases are treated.
The Oxford Science Park was created by Magdalen College Oxford in 1991 as part of its mission to support discovery, innovation, and entrepreneurship. It is home to world-class research, engineering, technology and clinical expertise, and aims to be environmentally, economically, and socially sustainable.
“We look forward to continuing the development of our Oxford presence and partnerships,” said Dr. David Agus, founding director and CEO of the Ellison Institute. “These acquisitions give us greater capacity to undertake critical biomedical research as well as the educational initiatives of the Institute in collaboration with Oxford University.”
Rory Maw, CEO of The Oxford Science Park, said, “We’re delighted to welcome the Ellison Institute to the Park and look forward to working with the team to help deliver their vision for the new Oxford campus. This commitment will reinforce the ground-breaking research and development already taking place on the Park, delivering benefits and opportunities for our occupiers and the wider Oxford innovation ecosystem.”
READ MORE: Oxford-based Physiomics signs new contract with Cancer Research UK
